TrialBMC cancer2018

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.

Ping-Tee Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.